SWOG clinical trial number
CTSU/CALGB 51101
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma.
Closed
Abbreviated Title
Randomized Ph II of myeloablative vs. non-myeloablative consolidation in CNS b-cell lymphoma
Activated
07/01/2012
Closed
05/02/2017
Participants
CTSU
Research committees
Lymphoma
Treatment
Etoposide
Filgrastim
GM-CSF
Leucovorin + 5-FU
Methotrexate
Rituximab
Temozolomide
Thiotepa
Carmustine
Cytarabine
Eligibility Criteria Expand/Collapse
SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase